Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors

Focus: 

To test a novel technology for delivering high-dose radiation to solid cancers that cannot be removed surgically

Anticipated Impact: 

Safer, more effective treatment of radiation-resistant solid cancers

Abstract: 

A key challenge in radiation therapy for cancer is achieving uniform, localized delivery of high doses without exceeding normal tissue tolerance. Dr. Fisher and his team are developing an injectable “radiogel” that provides controlled, high-dose delivery of yttrium-90 (90Y) to solid tumors that cannot be removed surgically. The product consists of a suspension of 90Y-phosphate microspheres in a sterile solution, which is liquid at the time of injection but solidifies at body temperature to capture the microspheres at the site of injection and limit radiation exposure to surrounding normal tissues. Additional potential advantages to the radiogel technology include low-cost ingredients, ease of use, and safety for both patients and health-care workers. The radiogel technology could be used in the US and internationally to treat a variety of radiation-resistant solid cancers, including those of the liver, brain, head and neck, kidney, and pancreas. In the proposed studies, clinicians from the University of Washington Department of Radiology will assess the technology’s biodistribution, radiation dose, homogeneity, activity in normal tissues, and ease of use in a preclinical tumor model. The commercialization partner, Advanced Medical Isotope Corporation (AMIC) of Kennewick, WA, has an exclusive option from Battelle to the associated intellectual property. If the proposed work is successful, AMIC intends to raise capital for additional testing, regulatory approval, seed manufacturing, and marketing.

Collaborating organizations: Advanced Medical Isotope Corporation, University of Washington 

Grant period ended early due to Dr. Fisher’s departure from Battelle-Pacific Northwest Division.

Cancer Diagnostics, Therapeutics

Grant Update

Principal Investigator:
Darrell Fisher
Grantee Organization:
Battelle, Pacific Northwest Division
Grant Title:
Injectable radiogels for high-dose therapy of non-resectable solid tumors
Grant Cohort and Year:
2011 Second Round Commercialization (04)
Grant Period:
05/15/2013 - 05/14/2014 (Completed)
Grant Amount:
$15,619

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Richland
Kennewick
Seattle

Legislative Districts:
8, 11, 34, 36, 37, 43, 46

Health Impacts

Cancer Diagnostics, Therapeutics